Apple’s longtime secret endeavor, dubbed E5, to measure how much glucose is in someone’s body without needing to prick the skin for blood has hit some major milestones recently, Mark Gurman of Bloomberg reports, citing people familiar with the effort. The company now believes it could eventually bring glucose monitoring to market, sources told Bloomberg. Apple’s glucose monitoring system could ultimately find its way into the company’s smartwatch line and if perfected, "would be a boon to diabetics and help cement Apple as a powerhouse in health care," says Gurman. Stocks in the diabetes space include DexCom (DXCM), Tandem Diabetes (TNDM), Medtronic (MDT) and Insulet (PODD). See the top stocks recommended by analysts >>
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Read More on AAPL:
